Cardiol Therapeutics (TSE:CRDL) Issues Earnings Results

Cardiol Therapeutics (TSE:CRDL) released its earnings results on Wednesday. The company reported C($0.05) EPS for the quarter, FiscalAI reports.

Cardiol Therapeutics Price Performance

CRDL opened at C$2.42 on Friday. The firm has a market cap of C$278.96 million, a PE ratio of -6.21 and a beta of 0.27. The stock has a 50-day moving average price of C$1.65 and a 200-day moving average price of C$1.64. Cardiol Therapeutics has a 1 year low of C$1.23 and a 1 year high of C$2.45. The company has a debt-to-equity ratio of 0.48, a current ratio of 4.39 and a quick ratio of 6.84.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc ( NASDAQ: CRDL ) ( TSX: CRDL ) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company’s lead small-molecule drug candidate, CardiolRx¿, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure. The MAVERIC Program is evaluating CardiolRx¿ for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations.